bioMérieux signed an Agreement to acquire Neoprospecta, a Brazil-based company dedicated to data and genomics solutions for microbial risk management in food and pharma industries

Founded in 2011 Neoprospecta is a biotechnological company dedicated to the development and commercialization of innovative microbiological analysis, based on next generation DNA sequencing and biocomputational analysis. With a workforce of approximately 50 people, the company achieved about $2 million of consolidated sales in 2023.

Amongst various technologies and services in its portfolio, Neoprospecta has developed Neobiome™, a strategic tool for decision making based on microbiome information. This data and genomics analysis platform allows food and pharma industries to enhance the quality and safety of their production by helping track and control areas of contamination, assess and manage risk, improve processes, and define good practices for microbiological control.

With this acquisition, bioMérieux strengthens its Data & Genomics offer, composed of innovative pathogen and spoiler investigation tools to prevent contamination reinforcing its Augmented Diagnostics approach. The initial phase will expand data and genomics capabilities in Brazil and Latin America. Then, bioMérieux will gradually integrate Neoprospecta technologies into its unique portfolio and make them available in selected markets across the globe.

“We are very enthusiastic about having Neoprospecta’s talented team join us and welcome them to bioMérieux. Adding their analytical interface to our portfolio will help us provide faster diagnostic tools to food and pharma industries,” said Yasha Mitrotti, Executive Vice President, Industrial Applications at bioMérieux. “This acquisition illustrates bioMérieux’s commitment to pioneer next-generation developments in microbiology, genomics, data science, bioinformatics and digital tools with the aim of moving away from the simple communication of test results to the production of truly meaningful data and actionable insights for industries. Our customers are enabled to make better, more informed and faster decisions for augmenting quality assurance programs and protecting consumer’s health.”

Luiz Fernando Valter de Oliveira, Chief Executive Officer and co-founder of Neoprospecta added: “We are thrilled to join the bioMérieux family today. bioMérieux’s rich history of pioneering innovation in diagnostics makes them the ideal partner for us to accelerate our growth. Their global commercial network and leadership in the food and pharma microbiology markets will allow our technologies to reach even more customers worldwide while also empowering us to provide additional technologies and resources in Brazil and Latin America. Ultimately, this partnership will greatly enhance our ability to develop new products, introduce our technologies to new markets, and to better serve our existing customers in the food and pharma industries.”

Under the terms of the agreement, bioMérieux will acquire 100% ownership of Neoprospecta for an undisclosed amount. The transaction is expected to close in the coming months, once customary closing conditions have been met.